Key Event Components

Key Event Components (KECs) are used to describe Key Events (KEs) in a computable way, by defining an action, processes, and object term that maps to controlled vocabulary and ontology terms.
KECs on this page can be filtered by the action, process, and object terms, as well as by source ontologies.
Link to source ontology terms are provided in cases where the URL was available when the ontology terms were added to the AOP-Wiki database.
A complete list of all KECs is available in TSV format on the Downloads Page.

Showing 101 to 125 of 1139 KECs

ID	Action	Process	Object	Associated Key Events (KEs)


101	increased	aryl hydrocarbon receptor activity (GO:0004874)	aryl hydrocarbon receptor (PR:000003858)	18: Activation, AhR
102	disrupted	protein dimerization activity (GO:0046983)	aryl hydrocarbon receptor (PR:000003858)	None
103	disrupted	protein dimerization activity (GO:0046983)	aryl hydrocarbon receptor nuclear translocator (PR:000004303)	None
104	morphological change	developmental process (GO:0032502)	cardiovascular system (UBERON:0004535)	None
105	morphological change	abnormal cardiovascular system physiology (MP:0001544)		317: Altered, Cardiovascular development/function
106	increased	gene expression (GO:0010467)	prostaglandin G/H synthase 2 (PR:000013428)	1269: Increase, COX-2 expression
107	increased	androgen receptor activity (GO:0004882)	androgen receptor (PR:000004191)	25: Agonism, Androgen receptor
108	decreased	gene expression (GO:0010467)	vitellogenins (MESH:D014819)	285: Reduction, Vitellogenin synthesis in liver
109	decreased	egg quantity (VT:1000294)		2 Events 78: Reduction, Cumulative fecundity and spawning 972: Decreased fertility, Reduced number of oocytes ovulated
110	decreased		vitellogenins (MESH:D014819)	221: Reduction, Plasma vitellogenin concentrations
111	decreased	receptor-mediated endocytosis (GO:0006898)	vitellogenins (MESH:D014819)	309: Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development
112	decreased	oocyte growth (GO:0001555)		309: Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development
113	decreased	oocyte development (GO:0048599)		309: Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development
114	decreased		Luteinizing hormone (CHEBI:81568)	2 Events 129: Reduction, Gonadotropins, circulating concentrations 690: Reduced, Luteinizing hormone (LH), plasma
115	decreased		Follicle stimulating hormone (CHEBI:81569)	129: Reduction, Gonadotropins, circulating concentrations
116	decreased	calcium-transporting ATPase activity (GO:0005388)	calcium ion-transporting ATPase complex (GO:0090534)	51: Inhibition, Ca++ ATPase
117	increased		calcium ion (CHEBI:39124)	50: Increase, Ca++ (intracellular)
118	disrupted		mitochondrial respiratory chain (GO:0005746)	178: Mitochondrial electron transport chain, disrupted
119	decreased	ATP biosynthetic process (GO:0006754)	ATP (CHEBI:15422)	4 Events 40: Mitochondrial ATP production, decreased 1138: Uncoupling of oxidative phosphorylation, Reduced ability to generate ATP 1771: Decrease, Adenosine triphosphate pool 1472: Decrease, ATP production
120	increased	reactive oxygen species biosynthetic process (GO:1903409)	reactive oxygen species (CHEBI:26523)	1115: Increase, Reactive oxygen species
121	decreased		nitric oxide (CHEBI:16480)	193: Decreased, Nitric Oxide
122	decreased	long-term synaptic potentiation (GO:0060291)		166: Decreased, Long-term potentiation (LTP)
123	increased	oxidative stress (MP:0003674)		3 Events 209: Peptide Oxidation 1279: Increase, Oxidative Stress / Activation, PMK-1 P38 MAPK 1392: Increase, Oxidative Stress
124	decreased	transport (GO:0006810)	bile salt export pump (PR:000003549)	41: Inhibition, Bile Salt Export Pump (ABCB11)
125	increased	gene expression (GO:0010467)	bile acid receptor (PR:000011396)	288: Activation of specific nuclear receptors, Transcriptional change